Kornimate/medical-research-clean huggingface dataset:
trunks body blocks for postoperative analgesia in abdominal surgery

Conditions: Analgesia; Block

Summary: this study aims to the comparison of quadratus lumborum block 2 and transversus abdominis plan block for postoperative analgesia in abdominal surgery

this study aims to the comparison of quadratus lumborum block 2 and transversus abdominis plan block for postoperative analgesia in abdominal surgery. in abdominal surgeries, usg guided body blocks are performed for postoperative analgesia. for this purpose, transversus abdominis plan block (tapb) and quadratus lumborum block 2 (qlb 2) are frequently used blocks. the aim of this study was to evaluate for postoperative analgesia of preoperative trunk blocks, intraoperative hemodynamic changes with the unblocked control group, modified aldrete recovery score (mads) 9 in the recovery unit, numerical pain scale (nrs) in the service department, it is aimed to examine and compare the time it reaches on the 1st, 2nd and 24th hours after this period. patient satisfaction is also evaluated in the ward.

Eligibility criteria:
inclusion criteria: abdominal surgery exclusion criteria: cardio-respiratory disease anti-inflammatory treatment cognitive disorders written consent form haven't get history of relevant drug allergy infection of the skin at the site of the needle puncture area coagulopathy

Keywords: quadratus lumborum block transversus abdominis block postoperative analgesia
continuous arterial spin labeling (casl) mri for monitoring and prediction of drug therapy in alzheimers disease (ad)

Conditions: Alzheimer's Disease

Summary: examination of the correlation between the cerebral bloodflow and the clinical change under treatment with reminyl retard® and the prediction of clinical change by measuring the cerebral bloodflow in patients with mild to moderate alzheimer's disease


Eligibility criteria:
inclusion criteria: * possible alzheimer's disease according to icd-10 and nincds-adrda * underwritten study consent * no treatment with acetylcholinesterase inhibitors * mini-mental-state examination: 12-25 points * age: 50-80 years * orale contraception for women of child-bearing age exclusion criteria: * mental disorders * other diseases of the cns * severe illness * contraindication for mri-scan * contraindication for galantamin (reminyl retard®) * participation at other clinical trials
efficacy evaluation of tci153 probiotics for skin beautification

Conditions: Skin Condition

Summary: to assess tci153 prebiotics product on skin condition improvement


Eligibility criteria:
inclusion criteria: * healthy adults aged above 18 years old exclusion criteria: * subject who is not willing to participate in this study. * patients with diseases of the skin, liver, kidney. * subjects who have known cosmetic, drug or food allergies, difficulty in digestive tract absorption or disorder. * female who is pregnant or nursing or planning to become pregnant during the course of the study. * received facial laser therapy, chemical peeling or uv overexposure (\> 3 hr/week) in the past 4 weeks. * constant drug use * students who are currently taking courses taught by the principal investigator of this trial. * subject who is not willing to have their photos published in public.
a swiss study with atorvastatin in hyperlipidemic patients measuring ldl-cholesterol

Conditions: Hyperlipidemia

Summary: the proportion of patients achieving ldl-c target as defined by swiss cholesterol recommendations (agla-recommendations) across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.


Eligibility criteria:
inclusion criteria: * risk factors and diagnosis of dyslipidemia according to the agla-recommendations (see appendix b) at screening * ldl-c \< 6.0 mmol/l * triglyceride level \< 5.0 mmol/l. exclusion criteria: * subjects receiving higher than "usual maintenance" doses of lipid lowering therapy (llt) at screening.
virtual reality - chronic pain at-home pilot study

Conditions: Chronic Pain

Summary: this is a short pilot usability study of a virtual reality device for patients with chronic pain.

the investigators will conduct a study of patients with chronic pain to collect feasibility of recruitment data, adherence to therapy data, and preliminary effectiveness data. all patients will be in the active arm, this is not a randomized study. the intervention being piloted is the easevrx (appliedvr, los angeles, ca) vr hardware and software. easevrx incorporates evidence-based principles of cognitive behavioral therapy, mindfulness, and pain neuroscience education into an immersive and enhanced biofeedback experience. easevrx includes breathing training and relaxation response exercises that activate the parasympathetic nervous system. easevrx was designed for at-home use and comes with a sequence of daily immersive experiences. each session will include one vr experience, which is 2-16 minutes in length (average of 6 minutes). this study will last one week, or 7 total sessions (out of 56 total sessions). participants will complete one survey at 3 days over the telephone assessing pain, mood, adherence to the device, and overall satisfaction. then participants will complete an additional assessment when the device is returned after day 7, again assessing pain, mood, overall adherence to the device, and overall satisfaction. the investigators are recruiting participants from the vr usability study (irb # 2021-13108) who expressed interest in participating in further research. as this is a pilot feasibility trial, the plan is to recruit between 5 and 10 patients.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. chronic pain (using self-report) with pain intensity \>=4 and confirmed by icd-10 codes in medical record 3. fluency in english exclusion criteria: 1. inability to give informed consent 2. current or prior diagnosis of epilepsy, seizure disorder, dementia, migraines 3. medical condition predisposing to nausea or dizziness 4. hypersensitivity to flashing light or motion 5. no stereoscopic vision or severe hearing impairment 6. injury to eyes, face, or neck that prevents use of vr headset 7. currently pregnant, by self-report
early mitral valve repair versus watchful waiting for asymptomatic severe degenerative mitral regurgitation

Conditions: Degenerative Mitral Regurgitation (MR) Due to Leaflet Prolapse

Summary: degenerative mitral regurgitation (mr) due to leaflet prolapse is frequent and can be surgically repaired in the vast majority of patients. despite the efficacy of mitral valve repair, an ongoing international controversy exists regarding the need to perform early surgery in asymptomatic patients with severe mr and no sign of lv dysfunction in whom the probability of successful and durable repair is very high. in this group of patients, differing views of the risks of uncorrected severe mr exist: considered as benign by those supporting medical "watchful waiting" or associated with significant excess mortality/morbidity by those advocating early surgery. this controversy can only be resolved by a randomized controlled trial which is still lacking. the main objective is to demonstrate the superiority of early mitral valve repair in patients with asymptomatic severe mr due to leaflet prolapse compared to an initial conservative management in terms of all-cause death and cardiovascular morbidity during five years follow-up.

experimental group: in patients randomized to early mitral valve repair, surgery will be performed within 3 months after randomization. clinical interview will be performed at discharge, at 6 months and afterwards yearly until the end of follow-up. echocardiography will be performed at discharge, at 6 months and at the end of follow-up. control group: patients randomized to initial conservative management will be followed up by clinical interview and echocardiography every 6 months. patients will be instructed to report any change in functional status in a prompt manner. surgery will be indicated at the onset of symptoms or if one or more of the following occur during follow-up: lv end-systolic diameter \>40mm, lv ejection fraction \ 50mmhg.

Eligibility criteria:
inclusion criteria: * asymptomatic patients according history or an exercise test in those able to perform it if there is a doubt about the absence of symptoms * severe (grade iv) degenerative mr due to leaflet prolapse assessed by echocardiography * lv ejection fraction by simpson biplane method ≥60% and lv end-systolic diameter by tm echocardiography ≤40mm * sinus rhythm on the inclusion ecg * pulmonary artery pressure ≤50 mmhg by doppler echocardiography. * high probability of mitral valve repair * euroscore ii ≤ 3% exclusion criteria: * mitral stenosis or \> mild aortic valve disease (stenosis or regurgitation) * congenital heart disease (except patent foramen ovale or atrial septal defect) * patients with cardiac prostheses * previous myocardial infarction * previous cardiac surgery * extra cardiac comorbidity with life expectancy \< 5 years * recent history of psychiatric disease (including drug or alcohol abuse) * therapy with an investigational intervention at the time of screening or plan to enrol patient in additional intervention study during participation in this trial
global haemostatic methods following administration of bypassing agents to patients with haemophilia with inhibitors

Conditions: Hemophilia

Summary: background the treatment of haemophilia a and b has been revolutionized by the use of factor concentrate, both as prophylaxis and to treat bleeding episodes (on-demand treatment). however, despite its advantages, repeated treatment with factor concentrate can lead to development of inhibitors (antibodies) towards the coagulation factor in the concentrate. another patient group in which the bleeding symptoms are difficult to treat because of inhibitors towards coagulation factors, most commonly fviii, is patients with acquired haemophilia. patients with high antibody titers exhibit a deficient or no response to factor concentrates and usually need treatment with bypassing agents, namely factor eight inhibitor bypassing agent (feiba®, baxter) och recombinant activated factor vii (rfviia, novo-seven®, novo nordisk). the effect of the treatment cannot be accurately monitored by traditional coagulation tests. the aim of the study is to evaluate the utility of the global haemostatic methods in patients with haemophilia with inhibitors. the objective is to improve the monitoring of the treatment effect and thus increase the safety of the patient and the effectiveness of the treatment. patients and methods patients the primary cohort will consist of fifteen patients with inherited haemophilia with inhibitors as well as five adult patients with acquired haemophilia who are followed up at the coagulation department of the karolinska university hospital, stockholm, sweden. blood samples will be collected from those patients at specific time points (see design of the study) during the course of two years (for each patient). the treatment (type, dose, duration) will be determined by the treating physician. methods (selection) * thrombin generation (calibrated automated thrombogram, cat® and a commercial kit from siemens®). * overall haemostatic potential (ohp) design of the study timeframe for blood sampling: i) baseline (inclusion in the study), and ii) prior and after administration of bypassing agents to either treat bleeding symptoms or before an invasive procedure or as prophylaxis. data analysis the variations in coagulation markers measured as described above (methods) will be associated to the clinical symptoms (bleeding), the level of coagulation factors (if measurable) and the titers of the inhibitors.


Eligibility criteria:
inclusion criteria: * informed consent * meets the study population description exclusion criteria: * no informed consent age\<7 years

Keywords: hemophilia inhibitors thrombin
hydrotherapy versus classical rehabilitation after surgical rotator cuff repair

Conditions: Rotator Cuff Tears

Summary: postoperative rehabilitation following rotator cuff repair is important to promote tendon healing, restore strength, and recover normal function. the aim of this study is to assess whether aquatic rehabilitation is more efficient than classical rehabilitation (land-based session) in term of range of motion, function, and pain than classical rehabilitation (land-based session) after an arthroscopic repair of the rotator cuff.

introduction: postoperative rehabilitation following rotator cuff repair is important to promote tendon healing, restore strength, and recover normal function. aquatic rehabilitation in hot water allows body relaxation and well-being that promote patient conditioning for efficient rehabilitation and is appreciated by patients. the aim of this study is to assess whether aquatic rehabilitation is more efficient than classical rehabilitation (land-based session) in term of range of motion, function, and pain after an arthroscopic repair of the rotator cuff. methods: this prospective case-control clinical study is randomized 1:1 between rehabilitation with hydrotherapy and land-based (standard) rehabilitation. this superiority trial that included 84 patients that have benefited from an arthroscopic superior cuff repair. patients were evaluated clinically at 6 weeks, 3, 6 and 24 months and using ultrasound at 6 months. multivariable linear regressions were performed to determine if 2-year postoperative scores were associated with gender, body mass index (bmi), age at index operation, rehabilitation group (hydrotherapy vs standard), and baseline passive range of motion (prom) active range of motion (arom).

Eligibility criteria:
inclusion criteria: * 18 years old or more * arthroscopic cuff repair of supraspinatus tendon (with potentially concomitant of infraspinatus tendon repair, tenodesis or tenotomy of brachial biceps tendon, acromioplasty, and distal clavicle removal). exclusion criteria: * lesion of subscapularis tendon; * slap lesion; * second rotator cuff surgery; * frozen shoulder (i.e. forward flexion reduced of 25% or more); * inability to follow the study protocol
feasibility and functionality test of ada's ddss prototype

Conditions: Dyspnea

Summary: this study is to explore with a feasibility and functionality test the potential of the ada ddss prototype with cases of dyspnea patients using the data collected at the emergency department (ed) and the ward of internal medicine of the university hospital basel.

this is an observational i.e. non-interventional, prospective feasibility study, which assesses, through observation, the potential, functionality and diagnostic performance of the ada ddss prototype in evaluating patients presenting with dyspnea as primary predominant complaint to the ed. once the consent form is signed, the investigator documents patients' data, medical history, symptoms and findings with the ada ddss prototype. during the entire patient journey through the hospital (presentation at the ed through to admission in the ward of internal medicine) relevant information are collected and documented in the ada ddss prototype simultaneously to standard documentation by the medical staff. examination and treatment are carried out by the attending physician without being influenced or affected by the entry of data in the ada ddss prototype. there is no intervention/change made to the usual care, and therefore neither an intervention patient group nor a control patient group. the "usual care" that each patient receives is the control comparison point for the performance of the ada ddss. the diagnoses proposed by the tool at different times (after triage in the emergency centre, when transferred to the ward and when discharged from the hospital) are then compared with those of the attending physician.

Eligibility criteria:
inclusion criteria: * dyspnea as the main symptom when entering the emergency room * existence of written consent * the patient is able to speak, understand and read german or english. exclusion criteria: * inability or unwillingness to understand and comply with study procedures due to: * language problems * acute mental disorders * dementia * clinical instability (e..b. resuscitation treatment, non-invasive ventilation, etc.)

Keywords: ada ddss prototype diagnostic decision support system (ddss)
correlates of oral human papillomavirus infection in adolescents and young adults with behaviorally acquired hiv

Conditions: HIV Infection

Summary: the proposed study is a substudy of atn 106 and a cross sectional study intended to be conducted at each of the amtus newly participating in atn iii. the intent is to enroll all youth with behaviorally-acquired hiv who have enrolled in atn 106. the study involves a review of the subjects' medical chart and a collection of an oral rinse sample.

atn 114 is a cross-sectional substudy of atn 106. in addition to sharing data collected in atn 106, an oral rinse sample along with the subject's self reported history and medical chart abstraction of hpv vaccination status and medical chart abstraction of a history of oral condylomata, oral dysplasia and oral tumor viruses will be collected in atn 114. recruitment is expected to last approximately one year, similar to the same timeframe for atn 106. enrollment may be terminated earlier at the discretion of the atn executive committee and/or the atn 114 protocol team should atn 106 also terminate enrollment early. individuals who have agreed to participate in atn 106 may be simultaneously approached at any clinic visit, or, for community-based sites, contacted directly for participation in atn 114. site staff may also contact individuals via phone, e-mail, or any other agreed-upon methods of communication. site staff should try as much as possible to incorporate the study visit into a regularly scheduled clinic visit.

Eligibility criteria:
inclusion criteria * behaviorally acquired hiv-infection as indicated by medical chart abstraction or self-reported history of sexual risk and/or needle using behaviors; and * completion of the atn 106 study visit (the same day or up to a maximum of 14 calendar days). exclusion criteria * presence of serious psychiatric symptoms (e.g., active hallucinations, thought disorder) that would impair the individual's ability to complete the study measures; * visibly distraught (e.g., suicidal, homicidal, exhibiting violent behavior); or * intoxicated or under the influence of alcohol or other substances at the time of consent/assent for atn 114.
evaluation of a mobile phone app for veterans with ptsd

Conditions: Stress Disorders, Post-Traumatic; Veterans

Summary: the purpose of this study is to evaluate a mobile phone app designed to help veterans with ptsd. participants in this study will be randomized to receive one of 2 possible mobile phone apps. the term "randomized" means that which app a participant receives will not be based on any characteristic or behavior of the participant, but will be determined solely by chance like a flip of a coin.

participants will receive access to the mobile app "ptsd coach". participants will be randomized (by computerized coin flip) to one of two versions of the mobile app. all versions of the app will provide comprehensive information and tools for managing trauma symptoms, but one version of the app will provide personalized, confidential coaching messages delivered by either a veteran peer or clinical psychologist. participants will be asked to complete an online survey before using the mobile phone application and again 8 weeks later. participants will be provided with the option to complete a telephone interview after 8 weeks of using the mobile phone application. to be eligible, participants must be a u.s. military veteran, age 18 or older, have received a previous diagnosis of ptsd, and own an iphone or ipad device.

Eligibility criteria:
inclusion criteria: * u.s. military veteran * age 18 or older * previously diagnosed with ptsd * own an iphone or ipad device exclusion criteria: * no previous history of ptsd
acute effects of beet juice consumption on exercise capacity in heart failure

Conditions: Heart Failure

Summary: the purpose of this project will be to determine whether consumption of beet juice concentrate prior to exercise may acutely improve exercise tolerance in patients with heart failure.

participants will complete up to four study visits. the first visit will involve completion of the informed consent process followed by a screening for study eligibility. the screening will consist of questionnaires pertaining to detailed medical history, diet, physical activity, and health-related quality of life (kccq). anthropometric measures and a general health screening (including heart rate, resting blood pressure, and small blood (\<15 ml) and urine samples will be collected). volunteers meeting eligibility requirements will be scheduled for a screening maximal cardiopulmonary exercise test. immediately prior to the exercise treadmill test, each subject will have a resting ecg and blood pressure to determine whether there are any abnormalities that would contraindicate exercise testing. qualified subjects will then undergo a maximal cardiopulmonary exercise (cpx) test. following successful completion of the screening cpx test, volunteers meeting eligibility requirements will be scheduled for two testing visits, at least one week apart. at one visit, participants will consume a small cup of beet juice concentrate, and at the other, they will consume placebo. treatment will be double-blinded and administered in random order.

Eligibility criteria:
inclusion criteria: * new york heart association (nyha) class ii-iii heart failure * receiving optimal medical therapy * sedentary exclusion criteria: * smoking * changes in medication or major cardiovascular (cv) event or procedure within the previous 6 wk * fixed rate pacemaker * unstable angina * other co-morbidities or limitations that preclude safe participation in the exercise testing * plans for hospitalization or cardiac transplantation within the next 2 months * type 1 diabetes * refusal or inability to provide informed consent

Keywords: exercise heart failure fatigue physical endurance functional food
safety and efficacy of bimatoprost compared with latanoprost in patients with glaucoma or ocular hypertension

Conditions: Ocular Hypertension; Glaucoma

Summary: the study will compare the safety and efficacy of bimatoprost and latanoprost in patients with glaucoma or ocular hypertension


Eligibility criteria:
inclusion criteria: * ocular hypertension or chronic glaucoma * patient requires iop-lowering therapy in both eyes exclusion criteria: * uncontrolled medical conditions * hypersensitivity to study medications